

FIRST, DO NO HARM

The risks of overtreating children with epilepsy

Eunice Chuang¹, Marilisa M. Guerreiro⁴, Sara Y. Tsuchie¹,
Angelica Santucci², Carlos A. M. Guerreiro⁴, Maria Augusta Montenegro³

ABSTRACT - Background: Although overtreatment with antiepileptic drugs contributes to the morbidity associated with epilepsy, many children still are overtreated. **Objective:** To evaluate if the withdrawal of at least one antiepileptic drug (AED) in children with refractory epilepsy using polytherapy enable a better seizure control. **Method:** This was a prospective study. Children with refractory epilepsy using at least two AEDs were included. Once the patient, or guardian, agreed to participate in the study, one or more AED were slowly tapered off. The remaining AEDs dosages could be adjusted as needed, but a new AED could not be introduced. **Results:** Fifteen patients were evaluated, three girls; ages ranging from 3 to 18 (mean=8.7 years). After at least one AED withdrawal, two (13.5%) patients became seizure free, seizures improved >50% in 5 (33.5%) patients, did not change in 5 (33.5%), and seizure frequency became worse in 3 (20%). Adverse events improved in 12 patients (80%). **Conclusion:** The withdrawal of at least one AED is a valuable option in the treatment of selected children with refractory epilepsy.

KEY WORDS: epilepsy, children, antiepileptic drug, overtreatment.

Primeiramente, não causar dano: os riscos do excesso de medicações no tratamento da epilepsia na infância

RESUMO - Introdução: Apesar do tratamento excessivo com drogas antiepilépticas (DAE) contribuir para a morbidade associada à epilepsia, muitas crianças ainda são submetidas a politerapia desnecessária. **Objetivo:** Avaliar se a retirada de pelo menos uma DAE em crianças com epilepsia refratária utilizando politerapia pode proporcionar melhor controle das crises epiléticas. **Métodos:** Este foi um estudo prospectivo. Crianças com epilepsia refratária em uso de pelo menos duas DAE foram incluídas. Após assinatura do consentimento informado, uma ou mais DAE foram lentamente retiradas. As doses das outras DAE que não foram retiradas poderiam ser ajustadas se necessário, mas uma nova DAE não pode ser introduzida. **Resultados:** Quinze pacientes foram avaliados, três eram meninas, com idades entre 3 e 18 anos (média=8,7). Após a retirada de pelo menos uma DAE, 2 (13,5%) pacientes ficaram livre de crises, as crises melhoraram em 5 (33,5%), não mudaram em 5 (33,5%) e a frequência das crises pioraram em 3 (20%) pacientes. Os eventos adversos melhoraram em 12 pacientes (80%). **Conclusão:** A retirada de pelo menos uma DAE é uma opção válida no tratamento de crianças com epilepsia refratária.

PALAVRAS-CHAVE: epilepsia, infância, droga antiepiléptica, tratamento excessivo.

Most children with epilepsy become seizure free after the introduction of one antiepileptic drug (AED)^{1,2}. There is universal agreement that the prescription of a single agent at the lowest therapeutic dosage constitutes the best practice in the treatment of epilepsy^{3,4}. This is the only way to avoid the risks of AED overtreatment⁴. Despite that, the use of polytherapy remains, especially if the first AED fails to control the seizures.

It is known that the reduction of one or more AED

is possible without an increase in seizure frequency⁵⁻⁷. Moreover, AEDs may aggravate pre-existing seizures and trigger new seizure types⁸.

The objective of this study was to evaluate if the withdrawal of at least one AED in children with refractory epilepsy using polytherapy can improve seizure control.

METHOD

This was a prospective study conducted at the pediatric

Department of Neurology - State University of Campinas SP, Brazil (UNICAMP): ¹Aluna de Medicina; ²Neurologista Infantil; ³Professora Doutora; ⁴Professor Titular. Eunice Chuang and Sara Y. Tsuchie are medical students and received a scholarship from CNPq.

Received 4 August 2006. Accepted 30 October 2006.

Marilisa M. Guerreiro, MD, PhD - Department of Neurology - FCM/Unicamp - P.O. Box 6111 - 13083-970 Campinas SP - Brazil. E-mail: guga@fcm.unicamp.br

epilepsy clinic of our University Hospital from January 2005 to December 2005. Inclusion criteria consisted of age between 1 and 18 years-old, diagnosis of refractory epilepsy, use of at least two AEDs, signature of informed consent approved by the Ethical Committee of our institution.

Once the patient, or guardian, agreed to participate in the study, one or more AEDs were slowly tapered off. The remaining AEDs dosages could be adjusted as needed, but a new AED could not be introduced.

After drug withdrawn we assessed seizure frequency and adverse events. Routine visits were scheduled and patients were instructed to seek medical care at our institution as needed, especially in case of seizure exacerbation.

RESULTS

Fifteen patients met the inclusion criteria and were included in the protocol, three girls and 10 boys; ages ranging from 3 to 18 (mean=8.7 years). Table 1 shows the characteristics of the patients.

After at least one AED withdrawal, two (13.5%)

patients became seizure free, seizures improved >50% in 5 (33.5%) patients, did not change in 5 (33.5%), and seizure frequency became worse in 3 (20%). Adverse events improved in 12 patients (80%; Table 2).

It should be noted that due to ethical issues, the doses of the remaining AED could be adjusted as needed. This probably contributed to seizure improvement in two patients (patients 2 and 8). However, five patients (patients 9, 10, 12, 13 and 14) presented improvement in seizure control after the withdrawal of one AED, without any modification in the remaining AEDs dosages.

DISCUSSION

There is no question that seizure freedom is the main goal for patients, families and doctors dealing with epilepsy. However, a small percentage of children

Table 1. Characteristics of the patients.

ID	Gender/Age	Etiology of epilepsy	Neuroimaging	Type of epileptic syndrome	Neurological examination
1	5/F	Chiari II malformation	Hydrocephalus	Partial	Developmental delay, macrocephaly, lower limb hypotonia and paresis
2	12/M	Criptogenic	Normal	Partial	Normal
3	3/F	Criptogenic	Normal	Indetermined	Developmental delay
4	15/M	Neonatal complications (mainly hypoglicemia)	Gliososis	Generalized (Lennox-Gastaut syndrome)	Developmental delay, tetraparesis
5	6/M	Brain malformation	Bilateral schizencefaly	Generalized (Lennox-Gastaut syndrome)	Developmental delay, tetraparesis, subnormal vision
6	13/M	Perinatal complications	Periventricular leucomalacia	Generalized (Lennox-Gastaut syndrome)	Developmental delay, tetraparesis
7	3/M	Neonatal complication (mainly prematurity)	Hydrocefalus	Generalized (West syndrome)	Developmental delay, tetraparesis
8	12/M	Unkown	Normal	Partial	Developmental delay, mental retardation
9	5/M	Hypoxic ischemic Encephalopathy	Focal atrophy	Generalized (Lennox-Gastaut syndrome)	Developmental delay, hypotonia
10	12/M	Unknown	Normal	Generalized (Lennox-Gastaut syndrome)	Developmental delay, mental retardation
11	18/M	Unknown	Normal	Generalized (Lennox-Gastaut syndrome)	Developmental delay, mental retardation
12	6/M	Meningoencephalitis	Multicystic leucomalacia	Generalized (Lennox-Gastaut syndrome)	Developmental delay, tetraparesis and microcephaly
13	8/M	Myoclonic atstatic epilepsy	Normal	Generalized	Developmental delay, mental retardation
14	10/M	Criptogenic	Normal	Generalized (Lennox-Gastaut syndrome)	Developmental delay, mental retardation
15	4/F	Meningoencephalitis	Normal	Generalized (Lennox-Gastaut syndrome)	Developmental delay, mental retardation, global hypotonia

Table 2. Adverse events and seizure control after AED withdrawal.

ID	AED	Adverse event	Number of seizures at baseline	AED withdrawn	Adverse event after AED withdrawal	Seizures after AED withdrawal	Follow-up
1	DPH (6.5 mg/kg/d) PB (3.6 mg/kg/d)	Apathy	4 / day	PB	Improved	Worse	-
2	CBZ (15 mg/kg/d) DPH (5 mg/kg/d) CLB (5 mg/d)	None	20 / day	CLB DPH ↑ CBZ (22,5 mg/kg/d)	No improvement	Improved (seizure-free)	12 months
3	LTG (6 mg/kg/d) VA (25 mg/kg/d) CLB (20 mg/d)	None	1 / week	VA CLB ↑ LTG (200 mg)	Improved	No improvement	10 months
4	VA (29 mg/kg/d) LTG (8,8 kg/d) TPM (5,8 mg/kg/d) CZP (0,5 mg/kg/d) NTZ (5 mg/kg/d)	Somnolence	2-3 / day	CZP NTZ	Improved	No improvement	6 months
5	CLB (10 ml/d) LTG (200 mg/d) VGB (1000 mg/d)	None	20 / day	VGB	No improvement	Worse	-
6	NTZ (15 mg/d) CBZ (1000 mg/d) PB (100 mg/d)	Somnolence, apathy, poor school attendance/ performance	3-10 / day	PB	Improved	No improvement	12 months
7	VA (40 mg/kg/d) CLB (2 mg/kg/day) VGB (100 mg/kg/day)	Somnolence, apathy	Daily seizures	VGB ↑ VA (50 mg/kg/day) ↑ CLB (2.2mg/kg/d)	Improved	No improvement	8 months
8	VA (18 mg/kg/day) FB (5 mg/kg/day) CZP (0.5 mg/day)	Somnolence, apathy	15 / day	PB CZP ↑ VA (25 mg/kg/day)	Improved	Improved (seizure-free)	12 months
9	FB (3 mg/kg/day) VA (56 mg/kg/day) CLB (40 mg/day)	Somnolence, apathy	5 / day	PB	Improved	Improved: 0-2 seizures / day	6 months
10	LTG (350 mg/day) CLB (45 mg/day) TPM (150 mg/day)	Somnolence, apathy	4 / day	TPM	Improved	Improved 80%	12 months
11	CZP (3.5 mg/day) CBZ (900 mg/day) VA (250 mg/day)	None	9 / week	VA	No improvement	Worse	-
12	DPH (7 mg/kg/day) PB (3.6 mg/kg/day)	Somnolence, apathy, gun hypertrophy, hypertrichosis	30 / day	DPH	Improved	Improved: 0-3 seizures/day	2 month
13	LTG (400 mg/day) CZP (3 mg/day)	Somnolence, apathy	2 / week	LTG	Improved	Improved: 1/month	3 month
14	TPM (3 mg/kg/day) CLB (20 mg/day) VA (39 mg/kg/day)	Somnolence, apathy, lost of weight	15 / day	TPM	Improved	Improved: 5 seizures / day	1 month
15	PB (5 mg/kg/dia) VA (30 mg/dkg/day) CZP (1 mg/day)	Somnolence, apathy	4 / day	PB	Improved	No improvement	3 months

AED, antiepileptic drug; CBZ, carbamazepine; CLB, clobazam; CZP, clonazepam; DPH, phenytoin; PB, phenobarbital; TPM, topiramate; VA, valproate; LTG, lamotrigina; NTZ, nitrazepam; VGB, vigabatrin.

will present refractory seizures, and will not become seizure-free despite adequate AED treatment⁹⁻¹¹. Epilepsy generally demands prolonged AED treatment which is often associated with drug toxicity, especially when there is the use of an excessive – and sometimes unnecessary – number of AEDs^{4,12-14}.

Although there is increasing awareness that over-treatment with AEDs contributes to the morbidity associated with epilepsy⁴, many children still are over-treated. One possible explanation can be the fact that seizures are probably one of the most frightening event a parent can experience. For that reason, parents often will take the child with refractory epilepsy to as many doctors as needed to have their seizures controlled. In addition, most parents will try almost anything if there is a small hope of seizure freedom. As for doctors, it is sometimes too hard to resist the family's desperate question "Can we add a new drug?"

Our findings show that the reduction of one or more AED is possible without an increase in seizure frequency, which is in keeping with other studies⁵⁻⁷. In addition, two patients became seizure free.

It should be kept in mind that the outcome of epilepsy treatment should not be measured only by the percentage of seizure reduction¹⁵. Quality of life is related not only to seizure control, but also to adverse events. We found that the withdraw of one AED provided a considerable improvement in the adverse events of five (33.5%) patients despite of no improvement in seizure control. This enable a better quality of life, and families referred that their children were feeling much better, despite no seizure control.

Epilepsy is a frightening condition, and some families cannot cope with a single febrile seizure. However, it is surprising how well many parents of a severely handicapped child – and above all, the children themselves – can sometimes cope very well with seizures. After the protocol, the substantial improvement in drug related adverse events enabled one of our patients with cerebral palsy to go back to school (patient 6).

One possible limitation of our study was that, according to ethical issues, the remaining AEDs dosages could be adjusted as needed. Higher doses of the remaining AED probably contributed to seizure improvement in two patients. However, five patients presented improvement in seizure control after the withdraw of one AED, without any modification in the remaining AEDs dosages.

We conclude that although a larger sample is needed in order to confirm our findings, the reduction of one AED in selected children with refractory epilepsy can be associated with less adverse events and better quality of life without worsening of seizure frequency. In addition, a few patients may present an improvement in seizure control.

REFERENCES

1. Camfield CS, Camfield P, Gordon K, Smith B, Dooley J. Outcome of childhood epilepsy: a population-based study with a simple scoring system for those treated with medication. *J Pediatr* 1993;122:861-868.
2. Silva M, MacArdle B, MaGowan M, et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. *Lancet* 1996; 347:709-713.
3. Baulac M. Rational conversion from antiepileptic polytherapy to monotherapy. *Epileptic Disord* 2003;5:125-132.
4. Holmes GL. Overtreatment in children with epilepsy. *Epilepsy Res* 2002;52:35-42.
5. Fischbacher E. Effect of reduction of anticonvulsants on wellbeing. *Br Med J (Clin Res Ed)* 1982;285:423-424.
6. Schmidt D. Reduction of two-drug therapy in intractable epilepsy. *Epilepsia* 1983;24:368-376.
7. Alvarez N. Discontinuance of antiepileptic medications in patients with developmental disability and diagnosis of epilepsy. *Am J Ment Retard*. 1989;93:593-595.
8. Guerrini R, Belmonte A, Genton P. Antiepileptic drug-induced worsening of seizures in children. *Epilepsia*. 1998;39(Suppl 3):S2-S10.
9. Ko TS, Holmes GL. EEG and clinical predictors of medically intractable childhood epilepsy. *Clin Neurophysiol* 1999;110:1245-1251.
10. Huttenlocker PR, Hapke RJ. A follow-up study of intractable seizures in childhood. *Ann Neurol* 1990;28:699-705.
11. Ferngren H, Akerstrom I, Rane A. Mono or polypharmacotherapy in institutionalized epileptic children with severe mental retardation? A team approach for optimizing antiepileptic therapy. *Acta Paediatr Scand* 1991;80:458-465.
12. Dooley J, Gordon K, Camfield C, Smith E. Discontinuation of anticonvulsant therapy in children free of seizures for 1 year: a prospective study. *Neurology* 1996;46:969-974.
13. Shinnar S, Berg AT, Moshé SL, et al. Discontinuing antiepileptic drugs in children with epilepsy: a prospective study. *Ann Neurol* 1994;35: 534-545.
14. Shorvon SD, Reynolds EH. Unnecessary polypharmacy for epilepsy. *Br Med J* 1977;1:1635-1637.
15. Vickery BG, Hay R, Engel J. Outcome assessment for epilepsy surgery: the impact of measuring health-related quality of life. *Ann Neurol* 1995; 37:158-166.